A Study of Anlotinib in Patients With Hepatocellular Carcinoma
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).
Hepatocellular Carcinoma
DRUG: Anlotinib
12-week Progression-free survival rate(PFR 12w), From randomization，each 42 days up to PD or death(up to 24 months)
Time to Progression(TTP), From randomization，each 42 days up to PD or death(up to 24 months)|24-week Progression-free survival rate(PFR 24w), From randomization，each 42 days up to PD or death(up to 24 months)|Serum Alpha-Fetoprotein level (AFP), From randomization up to 24 months|Overall Survival (OS), From randomization until death (up to 24 months)|Objective Response Rate (ORR), each 42 days up to intolerance the toxicity or PD (up to 24 months)|Disease Control Rate (DCR), each 42 days up to intolerance the toxicity or PD (up to 24 months)
To assess the primary effects and safety of Anlotinib with placebo in patients with Hepatocellular Carcinoma(HCC).